The Evolution of Medical Countermeasures for Ebola Virus Disease: Lessons Learned and Next Steps.
Ian CrozierKyla A BritsonDaniel N WolfeJohn D KlenaLisa E HensleyJohn S LeeLarry A WolfraimKimberly L TaylorElizabeth S HiggsJoel M MontgomeryKaren A MartinsPublished in: Vaccines (2022)
The Ebola virus disease outbreak that occurred in Western Africa from 2013-2016, and subsequent smaller but increasingly frequent outbreaks of Ebola virus disease in recent years, spurred an unprecedented effort to develop and deploy effective vaccines, therapeutics, and diagnostics. This effort led to the U.S. regulatory approval of a diagnostic test, two vaccines, and two therapeutics for Ebola virus disease indications. Moreover, the establishment of fieldable diagnostic tests improved the speed with which patients can be diagnosed and public health resources mobilized. The United States government has played and continues to play a key role in funding and coordinating these medical countermeasure efforts. Here, we describe the coordinated U.S. government response to develop medical countermeasures for Ebola virus disease and we identify lessons learned that may improve future efforts to develop and deploy effective countermeasures against other filoviruses, such as Sudan virus and Marburg virus.